MONTREAL, QUEBEC, May 31 (MARKET WIRE) —
ZoomMed Inc. (TSX VENTURE: ZMD), creator of the ZRx Prescriber, the e-Pic
communication network and the ZRx Pharma communication network announces
a second and final closing of the offering previously announced on April
27, 2010. The second closing, for gross proceeds of $500,000, added to
the previous closing, represents total gross proceeds of $2,500,000 for
the private placement. As part of this second closing, 2,500,000 shares
of ZoomMed were issued at a price of $0.20 per share, therefore totaling
12,500,000 issued shares at a price of $0.20 per share.
ZoomMed announced its intention to raise a minimum of $2,000,000 up to a
maximum of $2,700,000 through a non-brokered private placement of units.
Each unit, priced at $0.20, is comprised of one common share of ZoomMed.
A minimum of 10,000,000 and a maximum of 13,500,000 common shares of
ZoomMed could have been issued under this private placement.
Use of proceeds will be used to develop new services, which are more and
more requested, and marketing activities in order to increase revenues
and Cash Flows.
About the ZRx Prescriber
ZoomMed developed the ZRx Prescriber, a technologically innovative Web
application that enables physicians to use a wireless device, such as the
IPod Touch(TM), IPhone(TM), other PDA’s or computers, to rapidly write
and deliver scripts. The ZRx Prescriber is quick, efficient and
intuitive. Since it is a stand-alone product, it can easily be integrated
to any Electronic Medical Record application (EMR).
About the e-Pic communication network
ZoomMed’s e-Pic communication network allows intercommunications between
physicians who use the ZRx Prescriber and pharmacists who are members of
the network. Thus, physicians and pharmacists can transfer, capture
(scan), and electronically receive prescription information and
prescription renewal information through this high speed and entirely
secure network.
About the ZRx Pharma communication network
ZRx Pharma communication network, the new revolutionary communication
tool, allows information dissemination and intercommunication between
pharmaceutical corporations and physicians using the ZRx Prescriber, such
as; continuing medical education, new product launches, medical training,
major medical alerts, clinical studies and surveys.
Forward-Looking Statements
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may
constitute forward-looking statements. Such statements, based as they are
on the current expectations of management, inherently involve numerous
risks and uncertainties, known and unknown, many of which are beyond
ZoomMed’s control. Such risks include but are not limited to: the impact
of general economic conditions, changes in the regulatory environment in
the jurisdictions in which ZoomMed does business, stock markets
volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation, as well as other risks disclosed in
public filings of ZoomMed. Consequently, actual future results may differ
materially from the anticipated results expressed in the forward-looking
statements. The reader should not place undue reliance, if any, on the
forward-looking statements included in this news release. These
statements speak only as of the date made and ZoomMed is under no
obligation and disavows any intention to update or revise such statements
as a result of any event, circumstances or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Contacts:
ZoomMed Inc.
Mr. Yves Marmet
President and Chief Executive Officer
450-678-5457, Ext 228
info@zoommed.com
www.zoommed.com
Copyright 2010, Market Wire, All rights reserved.